title: PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia.
abstract: This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.
authors: Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
authors: Carlos Eduardo dos Santos
authors: CE
authors: Ferreira
authors: Francisco Antônio Helfenstein
authors: FA
authors: Fonseca
authors: Cristóvão Luis Pitangueira
authors: CL
authors: Mangueira
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000628:therapy*; D006801:Humans; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000276:immunology*; D034622:RNA Interference; D012697:Serine Endopeptidases / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D008078:Cholesterol, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases